Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?

被引：0
|
作者：
Ling, James [1 ]
Chow, Elaine [1 ,2 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Phase Clin Trial Ctr 1, Hong Kong, Peoples R China
来源：
MED | 2024年 / 5卷 / 08期
关键词：
D O I：
10.1016/j.medj.2024.06.010
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Previously, no randomized controlled trials investigated the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) as the primary endpoint in patients with diabetes and chronic kidney disease. In the FLOW trial, Perkovic et al. showed that once-weekly semaglutide reduced kidney failure, kidneyrelated death, and cardiovascular death by 24% as compared with placebo in patients with type 2 diabetes at high risk of renal progression.
引用
收藏
页码：845 / 847
页数：3
相关论文
共 50 条
  • [1] Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
    Khan, Irfan
    Lanktree, Matthew B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (40) : E1345 - E1345
  • [2] Glucagon-like peptide-1 receptor agonists to treat chronic kidney disease associated with type 2 diabetes
    Khan, Irfan
    Lanktree, Matthew B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2025, 197 (06) : E165 - E166
  • [3] Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
    Mosenzon, Ofri
    Schechter, Meir
    Leibowitz, Gil
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 347 - 360
  • [4] Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
    Guyton, Justinne
    Jeon, Michelle
    Brooks, Amie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (21) : 1739 - 1748
  • [5] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [6] Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes
    Sato, Tetsuhiko
    Azuma, Yoshinori
    Ozone, Chikafumi
    Okazaki, Mikako
    Takeda, Asami
    Okada, Manabu
    Futamura, Kenta
    Hiramitsu, Takahisa
    Goto, Norihiko
    Narumi, Shunji
    Watarai, Yoshihiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (10): : 2597 - 2603
  • [7] Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
    Albogami, Yasser
    Cusi, Kenneth
    Daniels, Michael J.
    Wei, Yu-Jung J.
    Winterstein, Almut G.
    DIABETES CARE, 2021, 44 (06) : 1344 - 1352
  • [8] Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
    Jepsen, Mathies M.
    Christensen, Mikkel B.
    EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (03) : 231 - 243
  • [9] Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management
    Lambert, Lynn
    SA PHARMACEUTICAL JOURNAL, 2013, 80 (03) : 24 - 26
  • [10] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy, 2019, 36 : 798 - 805
12345